Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT03875183

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Innolife Co., Ltd. (from the registry)
Registry
  • NCT NCT03875183
  • EudraCT 2019-000511-89
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03875183. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-20 (actual); primary completion 2022-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
Acronym
TRACER-HF
Condition
Heart Failure
Condition
Reduced Ejection Fraction
Intervention (Drug)
INL1
Intervention (Other)
Placebo
Lead sponsor
Innolife Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03875183
Content hash
7e813417b7682214d78d6e85b08e8be93aa548247a40534b2c041d38adefed67